• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Nevro Corp.

    3/27/25 4:14:11 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    NEVRO CORP

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    64157F103

    (CUSIP Number)


    DAVID GOLDMAN
    GAMCO INVESTORS, INC., ONE CORPORATE CENTER
    RYE, NY, 10580
    9149215000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/20/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GAMCO INVESTORS, INC. ET AL
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GABELLI FUNDS LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,322,950.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,322,950.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,322,950.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.5 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GAMCO Asset Management Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    88,500.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    88,500.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    88,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.2 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GABELLI & Co INVESTMENT ADVISERS, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    712,450.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    712,450.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    712,450.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.9 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GGCP, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    WYOMING
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    Associated Capital Group, Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GABELLI MARIO J
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    NEVRO CORP
    (c)Address of Issuer's Principal Executive Offices:

    1800 BRIDGE PARKWAY, REDWOOD CITY, CALIFORNIA , 94065.
    Item 2.Identity and Background
    (a)
    This statement is being filed by one or more of the following persons: GGCP, Inc. (GGCP), GGCP Holdings LLC (GGCP Holdings), GAMCO Investors, Inc. (GBL), Associated Capital Group, Inc. (AC), Gabelli Funds, LLC (Gabelli Funds), GAMCO Asset Management Inc. (GAMCO), Teton Advisors, LLC (Teton Advisors), Keeley-Teton Advisors, LLC (Keeley-Teton), Gabelli & Company Investment Advisers, Inc. (GCIA), Morgan Group Holding Co., (MGH), G.research, LLC (G.research), MJG Associates, Inc. (MJG Associates), Gabelli Securities International (Bermuda) Limited (GSIL), Gabelli Foundation, Inc. (Foundation), Mario Gabelli, LICT and CIBL. Those of the foregoing persons signing this Schedule 13D are hereinafter referred to as the Reporting Persons.
    (b)
    GAMCO is a New York corporation and GBL and MGH are Delaware corporations, each having its principal business office at One Corporate Center, Rye, New York 10580. GGCP is a Wyoming corporation and AC and GCIA are Delaware corporations each having its principal business office 191 Mason Street, Greenwich, CT 06830. GGCP Holdings is a Delaware limited liability corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. G.research is a Delaware limited liability company having its principal officers at One Corporate Center, Rye, New York 10580. Gabelli Funds is a New York limited liability company having its principal business office at One Corporate Center, Rye, New York 10580. Teton Advisors is a Delaware limited liability company having its principal place of business at 189 Mason Street, Greenwich, CT 06830. Keeley-Teton Advisors is a Delaware limited liability company having its principal place of business at 141 W. Jackson Blvd., Chicago, IL 60604. MJG Associates is a Connecticut corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. The Foundation is a Nevada corporation having its principal offices at 165 West Liberty Street, Reno, Nevada 89501. LICT is a Delaware corporation having its principal place of business as 401 Theodore Fremd Avenue, Rye, New York 10580. CIBL, Inc. is a Delaware corporation having its principal place of business as 165 West Liberty Street, Suite 220, Reno, NV 89501.
    (c)
    GGCP makes investments for its own account and is the manager and a member of GGCP Holdings which is the controlling shareholder of GBL and AC. GBL, a public company whose stock is quoted on the OTCQX platform, is the parent company for a variety of companies engaged in the securities business, including certain of those named below. AC, a public company listed on the New York Stock Exchange, is the parent company for a variety of companies engaged in the securities business, including certain of those listed below. GAMCO, a wholly-owned subsidiary of GBL, is an investment adviser registered under the Investment Advisers Act of 1940, as amended (Advisers Act). GAMCO is an investment manager providing discretionary managed account services for employee benefit plans, private investors, endowments, foundations and others. GCIA, a wholly owned subsidiary of AC, is an investment adviser registered under the Advisers Act and serves as a general partner or investment manager to limited partnerships and offshore investment companies and other accounts. As a part of its business, GCIA may purchase or sell securities for its own account. GCIA or its relying advisers, act as a general partner or investment manager of a number of funds or partnerships, including Gabelli Associates Fund, L.P., Gabelli Associates Fund II, L.P., Gabelli Associates Limited, Gabelli Associates Limited II E, Gabelli Intermediate Credit Fund L.P., GAMA Select Plus Master Fund, Ltd., GAMCO Medical Opportunities L.P., and Gabelli Multimedia Partners, L.P. G.research is a wholly owned subsidiary of MGH. G.research, is a broker-dealer registered under the Securities Exchange Act of 1934, as amended (1934 Act), which may as a part of its business purchase and sell securities for its own account. Gabelli Funds, a wholly owned subsidiary of GBL, is a limited liability company. Gabelli Funds is an investment adviser registered under the Advisers Act which provides advisory services for The Gabelli Equity Trust Inc., The Gabelli Asset Fund, The Gabelli Growth Fund, The Gabelli Convertible and Income Securities Fund Inc., The Gabelli Value 25 Fund Inc., The Gabelli Small Cap Growth Fund, The Gabelli Equity Income Fund, The Gabelli ABC Fund, The Gabelli Global Content & Connectivity Fund, The Gabelli Gold Fund, Inc., The Gabelli Multimedia Trust Inc., The Gabelli Global Rising Income & Dividend Fund, The Gabelli Capital Asset Fund, The Gabelli International Growth Fund, Inc., The Gabelli Global Growth Fund, The Gabelli Utility Trust, The Gabelli Utilities Fund, The Gabelli Dividend Growth Fund, The Gabelli Focused Growth and Income Fund, The Comstock Capital Value Fund, The Gabelli Dividend and Income Trust, The Gabelli Global Utility & Income Trust, The GAMCO Global Gold, Natural Resources, & Income Trust, The GAMCO Natural Resources, Gold & Income Trust, The GDL Fund, Gabelli Enterprise Mergers & Acquisitions Fund, The Gabelli ESG Fund, Inc., The Gabelli International Small Cap Fund, The Gabelli Healthcare & Wellness Rx Trust, The Gabelli Global Small and Mid Cap Value Trust, Gabelli Merger Plus+ Trust Plc, The Gabelli Global Financial Services Fund, The Gabelli Global Mini Mites Fund, The Gabelli Media Mogul Fund, The Gabelli Pet Parents Fund, The Gabelli U.S. Treasury Money Market Fund, Bancroft Fund Ltd. and Ellsworth Growth & Income Fund Ltd., Gabelli Growth Innovators ETF, Gabelli Love Our Planet & People ETF, Gabelli Automation ETF, Gabelli Commercial Aerospace & Defense ETF, Gabelli Financial Services Opportunities ETF (collectively, the Funds), which are registered investment companies. Gabelli Funds is also the investment adviser to The GAMCO International SICAV (sub-funds GAMCO Merger Arbitrage and GAMCO All Cap Value), a UCITS III vehicle. Teton Advisors, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The TETON Westwood Mighty Mitessm Fund, The TETON Convertible Securities Fund, The Teton Westwood Balanced Fund, and The TETON Westwood Equity Fund. The TETON Westwood Mighty Mites Fund and the Teton Convertible Securities Fund are subadvised by Gabelli Funds, and their holdings are included in this filing. Keeley-Teton, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The Teton Westwood Smallcap Equity Fund, The Keeley Small Cap Dividend Value Fund, The Keeley Small-Mid Cap Value Fund, and The Keeley Mid Cap Dividend Value Fund, as well as to institutional and individual clients. MJG Associates provides advisory services to private investment partnerships and offshore funds. Mario Gabelli is the sole shareholder, director and employee of MJG Associates. MJG Associates is the Investment Manager of Gabelli International Limited and Gabelli Fund, LDC. Mario J. Gabelli is the general partner of Gabelli Performance Partnership, LP. The Foundation is a private foundation. Mario Gabelli is the Chairman, a Trustee and the Investment Manager of the Foundation. Elisa M. Wilson is the President of the Foundation. LICT is a holding company with operating subsidiaries engaged primarily in the rural telephone industry. LICT actively pursues new business ventures and acquisitions. LICT makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is the Chief Executive Officer, a director, and substantial shareholder of LICT. CIBL is a holding company with interest in telecommunications operations, primarily in the rural telephone industry. CIBL actively pursues new business ventures and acquisitions. CIBL makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is a director, and substantial shareholder of CIBL. Mario Gabelli is the controlling stockholder, co-Chief Executive Officer and a director of GGCP and Chairman and Chief Executive Officer of GBL. He is the Executive Chairman of AC. Mario Gabelli is also a member of GGCP Holdings. Mario Gabelli is the controlling shareholder of MGH and indirectly of Teton Advisors and Keeley-Teton Advisors.
    (d)
    Not applicable.
    (e)
    Not applicable.
    (f)
    United States.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The Reporting Persons used an aggregate of approximately $12,232,191 to purchase the Securities reported as beneficially owned in Item 5. GAMCO and Gabelli Funds used approximately $507,801 and $7,643,448, respectively, of funds that were provided through the accounts of certain of their investment advisory clients (and, in the case of some of such accounts at GAMCO, may be through borrowings from client margin accounts) in order to purchase the Securities for such clients. GCIA used approximately $4,080,942 of client funds to purchase the Securities reported by it.
    Item 4.Purpose of Transaction
     
    Each of the Reporting Persons has purchased and holds the Securities reported by it for investment for one or more accounts over which it has shared, sole, or both investment and/or voting power, for its own account, or both. The Reporting Persons are engaged in the business of securities analysis and investment. The Reporting Persons analyze the operations, capital structure and markets of companies in which they invest, including the Issuer, on a continuous basis through analysis of documentation and discussions with knowledgeable industry and market observers and with representatives of such companies (often at the invitation of management). As a result of these analytical activities one or more of the Reporting Persons may issue analysts reports, participate in interviews or hold discussions with third parties, with management or with Directors in which the Reporting Person may suggest or take a position with respect to potential changes in the operations, management or capital structure of such companies as a means of enhancing shareholder values. Such suggestions or positions may relate to one or more of the transactions specified in clauses (a) through (j) of Item 4 of Schedule 13D including, without limitation, such matters as disposing of one or more businesses, selling the company or acquiring another company or business, changing operating or marketing strategies, adopting or not adopting, certain types of anti-takeover measures and restructuring the company capitalization or dividend policy. Each of the Reporting Persons intends to adhere to the foregoing investment philosophy with respect to the Issuer. However, none of the Reporting Persons intends to seek control of the Issuer or participate in the management of the Issuer, and any Reporting Person that is registered as an investment company under the Company Act will participate in such a transaction only following receipt of an exemption from the SEC under Rule 17d-1 under the Company Act, if required, and in accordance with other applicable law. In pursuing this investment philosophy, each Reporting Person will continuously assess the Issuers business, financial condition, results of operations and prospects, general economic conditions, the securities markets in general and those for the Issuers securities in particular, other developments and other investment opportunities, as well as the investment objectives and diversification requirements of its shareholders or clients and its fiduciary duties to such shareholders or clients. Depending on such assessments, one or more of the Reporting Persons may acquire additional Securities or may determine to sell or otherwise dispose of all or some of its holdings of Securities. Although the Reporting Persons share the same basic investment philosophy and although most portfolio decisions are made by or under the supervision of Mario Gabelli, the investment objectives and diversification requirements of various clients differ from those of other clients so that one or more Reporting Persons may be acquiring Securities while others are disposing of Securities. With respect to voting of the Securities, the Reporting Persons have adopted general voting policies relating to voting on specified issues affecting corporate governance and shareholder values. Under these policies, the Reporting Persons generally vote all securities over which they have voting power in favor of cumulative voting, financially reasonable golden parachutes, one share one vote, management cash incentives and pre-emptive rights and against greenmail, poison pills, supermajority voting, blank check preferred stock and super-dilutive stock options. Exceptions may be made when management otherwise demonstrates superior sensitivity to the needs of shareholders. In the event that the aggregate voting position of all Reporting Persons exceeds 25% of the total voting position of the Issuer, one or more of the filing persons may transfer voting and/or dispositive power over shares to independent committees of directors or the owners of such shares. Such committees vote and/or consider disposition of such shares independently of the Reporting Persons. Each of the Covered Persons who is not a Reporting Person has purchased the Securities reported herein as beneficially owned by him for investment for his own account or that of one or more members of his immediate family. Each such person may acquire additional Securities or dispose of some or all of the Securities reported herein with respect to him. Other than as described above, none of the Reporting Persons and none of the Covered Persons who is not a Reporting Person has any present plans or proposals which relate to or would result in any transaction, change or event specified in clauses (a) through (j) of Item 4 of Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    The aggregate number of Securities to which this Schedule 13D relates is 2,123,900 shares, representing 5.54% of the 38,372,026 shares outstanding as reported by the Issuer as of March 7, 2025. The Reporting Persons beneficially own those Securities as follows: GAMCO 88,500 shares 0.23%, Gabelli Funds 1,322,950 shares 3.45%, and GCIA 712,450 shares 1.86%.
    (b)
    Each of the Reporting Persons and Covered Persons has the sole power to vote or direct the vote and sole power to dispose or to direct the disposition of the Securities reported for it, either for its own benefit or for the benefit of its investment clients or its partners, as the case may be, except that (i) Gabelli Funds has sole dispositive and voting power with respect to the shares of the Issuer held by the Funds so long as the aggregate voting interest of all joint filers does not exceed 25% of their total voting interest in the Issuer and, in that event, the Proxy Voting Committee of each Fund shall respectively vote that Funds shares, (ii) at any time, the Proxy Voting Committee of each such Fund may take and exercise in its sole discretion the entire voting power with respect to the shares held by such fund under special circumstances such as regulatory considerations, and (iii) the power of Mario Gabelli, AC, GBL, and GGCP is indirect with respect to Securities beneficially owned directly by other Reporting Persons.
    (c)
    Information with respect to all transactions in the Securities which were effected during the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by each of the Reporting Persons and Covered Persons is set forth below: DATE SHARES PURCHASED PRICE /SOLD GABELLI & COMPANY INVESTMENT ADVISERS, INC. GABELLI ASSOCIATES FUND II 3/20/2025 4,750 5.7800 3/19/2025 10,850 5.7840 2/19/2025 2,350 5.7100 2/18/2025 2,500 5.7150 2/12/2025 3,550 5.7150 2/7/2025 200 5.7000 2/6/2025 9,350 5.7200 2/6/2025 4,850 5.7232 2/6/2025 24,300 5.7000 GABELLI ASSOCIATES FUND 3/20/2025 13,900 5.7800 3/19/2025 33,800 5.7840 2/19/2025 6,800 5.7100 2/18/2025 7,200 5.7150 2/12/2025 10,300 5.7150 2/7/2025 500 5.7000 2/6/2025 27,000 5.7200 2/6/2025 14,000 5.7232 2/6/2025 70,150 5.7000 GABELLI ASSOCIATES LIMITED II E 3/20/2025 8,800 5.7800 3/19/2025 21,600 5.7840 2/19/2025 4,350 5.7100 2/18/2025 4,450 5.7150 2/12/2025 6,550 5.7150 2/7/2025 300 5.7000 2/6/2025 17,050 5.7200 2/6/2025 8,900 5.7232 2/6/2025 44,350 5.7000 GABELLI ASSOCIATES LIMITED 3/20/2025 26,450 5.7800 3/19/2025 65,050 5.7840 2/19/2025 13,000 5.7100 2/18/2025 13,400 5.7150 2/12/2025 19,700 5.7150 2/7/2025 950 5.7000 2/6/2025 51,300 5.7200 2/6/2025 26,650 5.7232 2/6/2025 133,250 5.7000 GABELLI FUNDS, LLC GABELLI ABC FUND 3/10/2025 11,500 5.7300 3/3/2025 6,700 5.7363 2/21/2025 36,417 5.7295 2/20/2025 35,000 5.7200 2/11/2025 1,883 5.7100 2/6/2025 5,000 5.7171 2/6/2025 5,000 5.7699 COMSTOCK CAPITAL VALUE FUND 3/19/2025 1,500 5.7840 2/19/2025 1,000 5.7100 2/6/2025 7,500 5.7200 GABELLI ENTERPRISE M&A FUND 2/20/2025 25,000 5.7200 2/14/2025 9,000 5.7300 2/6/2025 3,000 5.7171 2/6/2025 3,000 5.7699 GAMCO MERGER ARBITRAGE UCITS 3/20/2025 39,200 5.7800 3/19/2025 100,550 5.7840 2/19/2025 19,150 5.7100 2/18/2025 19,000 5.7150 2/12/2025 29,750 5.7150 2/12/2025 400 5.7150 2/7/2025 1,300 5.7000 2/6/2025 74,500 5.7200 2/6/2025 38,700 5.7232 2/6/2025 193,400 5.7000 GDL FUND 3/25/2025 140,000 5.8300 3/7/2025 20,822 5.7800 3/6/2025 39,178 5.7800 2/27/2025 75,000 5.7400 2/24/2025 4,161 5.7300 2/21/2025 65,839 5.7300 2/14/2025 75,000 5.7200 2/7/2025 70,000 5.7200 2/6/2025 75,000 5.7300 GABELLI MERGER PLUS+ TRUST 3/20/2025 6,900 5.7800 3/19/2025 16,650 5.7840 2/19/2025 3,350 5.7100 2/18/2025 3,450 5.7150 2/12/2025 5,150 5.7150 2/7/2025 250 5.7000 2/6/2025 13,300 5.7200 2/6/2025 6,900 5.7232 2/6/2025 34,550 5.7000 GAMCO ASSET MANAGEMENT INC. 3/10/2025 8,500 5.7300 3/5/2025 15,000 5.7991 2/20/2025 15,000 5.7200 2/14/2025 15,000 5.7300 2/11/2025 29,000 5.7265 2/6/2025 6,000 5.7152
    (d)
    The investment advisory clients of, or partnerships managed by, GAMCO, Gabelli Funds, Teton Advisors and MJG Associates have the sole right to receive and, subject to the notice, withdrawal and/or termination provisions of such advisory contracts and partnership arrangements, the sole power to direct the receipt of dividends from, and the proceeds of sale of, any of the Securities beneficially owned by such Reporting Persons on behalf of such clients or partnerships. Except as noted, no such client or partnership has an interest by virtue of such relationship that relates to more than 5% of the Securities.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The powers of disposition and voting of Gabelli Funds, Teton Advisors, GAMCO, GCIA and MJG Associates with respect to Securities owned beneficially by them on behalf of their investment advisory clients, and of MJG Associates and GCIA with respect to Securities owned beneficially by them on behalf of the partnerships or corporations which they directly or indirectly manage, are held pursuant to written agreements with such clients, partnerships and funds.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    GAMCO INVESTORS, INC. ET AL
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:GENERAL COUNSEL
    Date:03/27/2025
     
    GABELLI FUNDS LLC
     
    Signature:DAVID GOLDMAN
    Name/Title:GENERAL COUNSEL
    Date:03/27/2025
     
    GAMCO Asset Management Inc.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:03/27/2025
     
    GABELLI & Co INVESTMENT ADVISERS, INC.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:03/27/2025
     
    GGCP, INC.
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:03/27/2025
     
    Associated Capital Group, Inc.
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:CHIEF LEGAL OFFICE
    Date:03/27/2025
     
    GABELLI MARIO J
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:03/27/2025
    Get the next $NVRO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:33 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:35 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:38 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    View All

    Nevro Enters Into Cooperation Agreement With Engaged Capital

    Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

    2/21/24 4:06:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Appoints Jon R. Shear as Vice President, Corporate Development

    REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

    4/19/21 7:00:00 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

    REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

    11/30/20 7:00:00 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Financials

    Live finance-specific insights

    View All

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    3/4/25 4:15:00 PM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    2/6/25 9:30:21 AM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Reports Third-Quarter 2024 Financial Results

    Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

    11/11/24 4:05:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    3/4/25 4:15:00 PM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    2/6/25 9:30:21 AM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

    REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

    1/21/25 4:30:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    SEC Filings

    View All

    SEC Form 15-12G filed by Nevro Corp.

    15-12G - NEVRO CORP (0001444380) (Filer)

    4/14/25 8:30:09 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Nevro Corp.

    EFFECT - NEVRO CORP (0001444380) (Filer)

    4/8/25 12:15:06 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

    SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

    4/4/25 3:49:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nevro upgraded by Jefferies with a new price target

    Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

    2/10/25 7:02:54 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

    2/7/25 8:27:53 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Nevro with a new price target

    Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

    12/3/24 7:38:11 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nevro Corp.

    SC 13G - NEVRO CORP (0001444380) (Subject)

    12/4/24 4:27:18 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nevro Corp.

    SC 13D/A - NEVRO CORP (0001444380) (Subject)

    11/14/24 5:31:36 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nevro Corp.

    SC 13G/A - NEVRO CORP (0001444380) (Subject)

    11/14/24 5:18:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care